Jinyoung Song

professor

Samsung Medical Center
Country flagSouth Korea

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (6)

Year:

2026

Kawasaki disease (KD) is an acute febrile illness of childhood that can lead to coronary artery aneurysms (CAAs), increasing the risk of thrombosis, stenosis, myocardial infarction (MI), and long-term cardiovascular events. Coronary complications are associated with giant aneurysms, male sex, and resistance to immunoglobulin therapy. MI symptoms are often non-specific, especially in young children, with the highest risk occurring within three months after disease onset. Revascularization strategies, adapted from adult acute coronary syndrome guidelines, include primary percutaneous coronary intervention (PCI), thrombolysis, and coronary artery bypass grafting (CABG), depending on timing, anatomy, and patient size. PCI is often challenging in this population due to small vessel size, heavy calcification, and luminal proliferation. Available treatment options include balloon angioplasty, stent implantation, rotational atherectomy, and intravascular lithotripsy. Balloon angioplasty in KD patients requires caution due to the risk of neo-aneurysm formation, particularly with high-pressure balloon dilatation. Thrombolysis remains an important option when PCI is not feasible. CABG, particularly using arterial grafts, offers excellent long-term patency and remains preferred for complex disease. Although PCI has higher re-intervention rates, long-term survival after PCI and CABG is comparable. Tailored approaches considering lesion complexity, hemodynamics, and patient-specific factors are essential in managing coronary complications in KD.

Year:

2025

BACKGROUND: Sacubitril/valsartan, an angiotensin receptor-neprilysin inhibitor (ARNI), is an established treatment for heart failure (HF) with reduced left ventricular ejection fraction. It has not been rigorously compared with angiotensin-converting enzyme inhibitors in children. PANORAMA-HF (Prospective Trial to Assess the Angiotensin Receptor Blocker Neprilysin Inhibitor LCZ696 Versus Angiotensin-Converting Enzyme Inhibitor for the Medical Treatment of Pediatric HF) is a randomized, double-blind trial that evaluated the pharmacokinetics and pharmacodynamics (PK/PD), safety, and efficacy of sacubitril/valsartan versus enalapril in children 1 month to <18 years of age with HF attributable to systemic left ventricular systolic dysfunction (LVSD). METHODS: Children with HF attributable to LVSD were randomized to sacubitril/valsartan versus enalapril to assess the efficacy and safety of sacubitril/valsartan at 52 weeks of follow-up. The primary end point of the study was to determine whether sacubitril/valsartan was superior to enalapril for the treatment of pediatric patients with HF attributable to systemic LVSD, assessed using a primary global rank end point consisting of ranking patients from worst to best on the basis of clinical events such as death, listing for urgent heart transplant, mechanical life support requirement, worsening HF, New York Heart Association (NYHA)/Ross class, Patient Global Impression of Severity (PGIS), and Pediatric Quality of Life Inventory physical functioning domain. The change from baseline to 52 weeks in NT-proBNP (N-terminal pro–B-type natriuretic peptide) was an exploratory end point. RESULTS: A total of 375 children (mean age, 8.1±5.6 years; 52% female) were randomized to sacubitril/valsartan (N=187) or enalapril (N=188). At week 52, no significant difference was observed between the 2 treatment arms in the global rank end point (Mann-Whitney probability, 0.52 [95% CI, 0.47–0.58]; Mann-Whitney odds, 0.91 [95% CI, 0.72–1.14]; P =0.42). At week 52, clinically meaningful reductions were observed in both treatment arms in NYHA/Ross, PGIS, Patient Global Impression of Change, and NT-proBNP, without significant differences between groups. Adverse events were similar between treatment arms (incidence: sacubitril/valsartan, 88.8%; enalapril, 87.8%), and the safety profile of sacubitril/valsartan was acceptable in children. CONCLUSIONS: In this study, sacubitril/valsartan did not show superiority over enalapril in the treatment of children with HF attributable to systemic LVSD using the prespecified global rank end point. However, both treatment arms showed clinically meaningful improvements over 52 weeks. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02678312.

Year:

2024

BACKGROUND Young adults with Fontan circulation (FC) face psychosocial, physical, and environmental challenges and are vulnerable to emotional distress. They need holistic intervention programs to face these problems and enhance their quality of life. This study developed and evaluated a cardiac and psychosocial rehabilitation (CPR) program for young adults with FC. METHODS AND RESULTS Thirty-eight young adults with FC aged 18–23 years were prospectively recruited from an outpatient clinic and randomized into a CPR group (n = 12) that underwent eight weekly group-based sessions combining a psychosocial program based on cognitive behavioral therapy with home-based cardiac rehabilitation (CR), a CR group (n = 12) that received only home-based CR, and a usual care control group (n = 12). The study assessed CPR program effectiveness based on the Hospital Anxiety and Depression Scale, self-efficacy, quality of life, and exercise capacity testing at three time points: pre-intervention, post-intervention, and four weeks post-intervention. Participants’ average ages were 19.75 (2.28), 19.65 (1.79), and 20.38 (1.85) years in the CPR, CR, and control groups, respectively; 50% (CPR group) to 53.8% (CR and control groups) of the participants were male. After eight weeks, depression and anxiety decreased, whereas self-efficacy and quality of life increased in the CPR group compared with the CR and control groups. The groups showed no differences in exercise capacity. CONCLUSION CPR can be part of an intervention for alleviating psychological distress and improving self-efficacy in young adults with FC. Efforts should be made to increase the efficacy of home-based CR.

Year:

2024

Background Heart transplantation is often limited by the availability of transplantable donor heart and understanding of donor aspects that would influence transplant outcomes becomes important. In this study, donor characteristics and their impact on the outcomes of pediatric heart transplantations performed in South Korea were investigated. Methods We reviewed the medical records of patients less than 18 years old who received heart transplantation between 2002 and 2022 in three tertiary hospitals located in South Korea. Results A total of 139 cases were enrolled. One‐year mortality was 10.4% and total mortality was 33.8%. Forty‐nine recipients (35.3%) showed biopsy‐proven rejections and 20 (14.4%) showed cardiac allograft vasculopathy during mean follow‐up of 6.4 ± 4.9 years. Six recipients (4.5%) showed left ventricle ejection fraction of less than 55% post‐transplantation. The mean age of the donors was 23.0 ± 15.4 years. The most common cause of death of the donors was unspecified illness (46.4%). Donors with a history of diabetes, hypertension, smoking, and alcohol consumption were 0%, 3.1%, 32.1%, and 34.4%, respectively. Mean total ischemic time was 191.6 ± 72.7 min, while total ischemic time was over 4 h in 37 patients (26.6%). There were no significant relationship between donor factors and survival. However, donor's history of drinking or cardiopulmonary resuscitation was significantly associated with acute rejection and donor's age with cardiac allograft vasculopathy. Conclusion Donor factors did not show significant impact on post‐transplant survival but some factors were predictive of post‐transplant rejection and cardiac allograft vasculopathy.

Year:

2024

Year:

2023

Collaborators (12)

Ching Kit Chen

-

SINGAPORE
View details

Jacek Kusa

Medical University of Silesia

POLAND
View details

Charles E. Canter

-

UNITED STATES
View details

Joan Sanchez-de-Toledo

Director del Área del Corazón

University of Pittsburgh

UNITED STATES
View details

Damien Bonnet

-

FRANCE
View details

Hyoung-Doo Lee

Prof

Pusan National University

SOUTH KOREA
View details

Sang-Yun Lee

MD, PhD, Prof

Seoul National University

SOUTH KOREA
View details

Kyunga Kim

Professor

Samsung Medical Center

SOUTH KOREA
View details

Joseph Rossano

Children's Hospital of Philadelphia

UNITED STATES
View details

Chad Mao

Children's Healthcare of Atlanta

UNITED STATES
View details

Sung‐A Chang

Samsung Medical Center

SOUTH KOREA
View details

Matthew Bock

Associate Professor

University of California, San Diego

UNITED STATES
View details